Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population.


Journal

Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343

Informations de publication

Date de publication:
11 2022
Historique:
revised: 12 08 2022
received: 09 05 2022
accepted: 25 08 2022
pubmed: 1 10 2022
medline: 22 10 2022
entrez: 30 9 2022
Statut: ppublish

Résumé

Immunostaining with p16 In this post-hoc analysis, 326 histology follow-up samples from a group of hrHPV-positive women were stained with p16 immunohistochemistry. All H&E samples were centrally revised. The pathologists reported their level of confidence in classifying the CIN lesion. Combining H&E and p16 staining resulted in a change of diagnosis in 27.3% (n = 89) of cases compared with the revised H&E samples, with a decrease of 34.5% (n = 18) in CIN1 and 22.7% (n = 15) in CIN2 classifications, and an increase of 18.3% (n = 19) in no CIN and 20.7% (n = 19) in CIN3 diagnoses. The level of confidence in CIN grading by the pathologist increased with adjunctive use of p16 immunohistochemistry to standard H&E. This study shows that adjunctive use of p16 immunohistochemistry to H&E morphology reduces the number of CIN1 and CIN2 classifications with a proportional increase in no CIN and CIN3 diagnoses, compared with standard H&E-based CIN diagnosis alone. The pathologists felt more confident in classifying the material with H&E and p16 immunohistochemistry than by using H&E alone, particularly during assessment of small biopsies. Adjunctive use of p16 immunohistochemistry to standard H&E assessment of CIN would be valuable for the diagnostic accuracy, thereby optimizing CIN management and possibly decreasing overtreatment.

Identifiants

pubmed: 36177908
doi: 10.1111/aogs.14459
pmc: PMC9812205
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p16 0
Hematoxylin YKM8PY2Z55
Eosine Yellowish-(YS) TDQ283MPCW
Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1328-1336

Informations de copyright

© 2022 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

Références

Mod Pathol. 2017 Jul;30(7):1021-1031
pubmed: 28304400
Int J Cancer. 2006 Sep 1;119(5):1095-101
pubmed: 16586444
Am J Clin Pathol. 2015 Dec;144(6):844-9
pubmed: 26572990
Am J Clin Pathol. 2016 Apr;145(4):524-30
pubmed: 27124943
Mod Pathol. 2016 Jan;29(1):51-9
pubmed: 26541274
J Low Genit Tract Dis. 2016 Jul;20(3):201-6
pubmed: 26855146
Int J Cancer. 2015 Feb 1;136(3):646-55
pubmed: 24923998
Acta Obstet Gynecol Scand. 2021 Mar;100(3):403-409
pubmed: 33037625
BMC Med. 2019 Dec 11;17(1):228
pubmed: 31829241
Acta Obstet Gynecol Scand. 2022 Nov;101(11):1328-1336
pubmed: 36177908
Mod Pathol. 2017 Feb;30(2):304-310
pubmed: 27739439
Int J Cancer. 2015 Jun 15;136(12):2741-51
pubmed: 24740700
Am J Surg Pathol. 2015 May;39(5):611-7
pubmed: 25602791
Arch Pathol Lab Med. 2012 Oct;136(10):1259-61
pubmed: 23020732
J Gynecol Oncol. 2010 Jun;21(2):87-92
pubmed: 20613897
Int J Cancer. 2021 Aug 1;149(3):707-716
pubmed: 33729551
Am J Surg Pathol. 2018 Aug;42(8):1001-1009
pubmed: 29697437
J Clin Pathol. 2018 Nov;71(11):981-988
pubmed: 30012698
BMJ. 2014 Oct 28;349:g6192
pubmed: 25352501
Am J Surg Pathol. 2008 Apr;32(4):502-12
pubmed: 18223479
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
Cancer Med. 2020 Apr;9(7):2454-2461
pubmed: 32022461
Int J Gynecol Pathol. 2013 Jan;32(1):76-115
pubmed: 23202792
Anticancer Res. 2022 May;42(5):2599-2606
pubmed: 35489732
Pathol Res Pract. 2017 Jul;213(7):723-729
pubmed: 28554769
J Clin Pathol. 2010 Nov;63(11):972-7
pubmed: 20924035
Obstet Gynecol. 2004 Aug;104(2):250-4
pubmed: 15291995
Expert Rev Anticancer Ther. 2016 Oct;16(10):1073-85
pubmed: 27598683
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2130-5
pubmed: 21245294

Auteurs

Renée M F Ebisch (RMF)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

L Lucia Rijstenberg (LL)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Gilda Ghazi Soltani (GG)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Judith van der Horst (J)

Department of Pathology, Deventer Hospital, Deventer, The Netherlands.

Judith E M Vedder (JEM)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Meyke Hermsen (M)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Remko P Bosgraaf (RP)

Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

Leon F A G Massuger (LFAG)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.

Chris J L M Meijer (CJLM)

Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Daniëlle A M Heideman (DAM)

Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Folkert J van Kemenade (FJ)

Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Willem J G Melchers (WJG)

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Ruud L M Bekkers (RLM)

Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.

Albert G Siebers (AG)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Johan Bulten (J)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH